Kyorin Pharmaceutical Co. has licensed the ex-Japan Asian rights of its overactive bladder treatment to Eisai Co. (TSE: 4523), a fellow Japanese pharma. Uritos® Tablets (imidafenacin) was discovered by Kyorin, which has marketed the product in Japan since 2007. Eisai will own marketing rights for China, India, Sri Lanka and ASEAN countries. Kyorin and Eisai will work together to get the product approved for sale in these countries. More details...